GSK2292767

Cat. No.:	HY-15280
CAS No.:	1254036-66-2
Molecular Formula:	$C_{24}H_{28}N_6O_5S$
Molecular Weight:	512.58
Target:	PI3K
Pathway:	PI3K/Akt/mTOR
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 125 mg/mL (243.86 mM; ultrasonic and warming and heat to 60°C)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	1.9509 mL	9.7546 mL	19.5091 mL
	5 mM	0.3902 mL	1.9509 mL	3.9018 mL
	10 mM	0.1951 mL	0.9755 mL	1.9509 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

GSK2292767 is a potent and selective inhibitor of PI3Kδ, with a pIC_{50} of 10.1. GSK2292767 showing greater than 500-fold selective over the other PI3K isoforms. GSK2292767 can be used for the research of respiratory disease[1].

IC_{50} & Target

PI3Kδ
10.1 (pIC_{50})

In Vivo

GSK2292767 exhibits high clearance (50 mL/min/kg) in vivo and low oral bioavailability (F < 2%) in a rat PK study[1].
GSK2292767 (0.01-1 μM) has no effect on QT interval, $T_{p\boxtimes e}$, or QRS and no significant risk of TdP arrhythmias in a rabbit cardiac ventricular wedge assay[1].
GSK2292767 protects against eosinophil recruitment with an ED_{50} of 35 μg/kg in the brown Norway rat acute OVA model of Th2 driven inflammation in the lungs of rats[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Down K, et, al. Optimization of Novel Indazoles as Highly Potent and Selective Inhibitors of Phosphoinositide 3-Kinase δ for the Treatment of Respiratory Disease. J Med Chem. 2015 Sep 24; 58(18): 7381-99.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA